Latest News

53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago – According to Phase 3 ‘482 study, the largest international multiple myeloma trial ever conducted with 1,718 patients involved, patients who receive denosumab (XGEVA) had a significantly lower rate of renal adverse events compared to zoledronic acid (10.0 percent versus 17.1 percent, p<0.001).…

Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2016. The talk will be given by Dr Laurent Garderet, Department of Hematology, Saint Antoine Hospital, Paris,…

Patient Advocacy sessions were again an integral part of EHA’s annual congress program! PDFs of all three patient advocacy sessions are now available. Click on the respective presentation to download the slides. We would like to thank CML Advocates Network for putting all together this information and circulating across all the involved groups.